VolitionRx (NYSE American: VNRX) Downgraded to Hold by Freedom Broker Amidst Nu.Q Platform Progress
- Freedom Broker downgraded VolitionRx to Hold.
- VolitionRx reports significant progress with its Nu.Q diagnostic platform, including peer-reviewed validation in sepsis and early-stage cancer detection above 95%.
- The company expanded its Fujifilm agreement, reduced debt by over $5 million, and holds more than 70 patents for its platform.
VolitionRx (NYSE American: VNRX) develops the Nu.Q diagnostic platform. Freedom Broker downgraded VolitionRx to Hold when the stock was priced at $0.19. The shares trade at $0.19, down $0.01, or 5.56%, on volume of 3,018,250 shares.
The downgrade comes as VolitionRx reports progress across its Nu.Q product lines. Its 2026 work includes peer-reviewed validation in sepsis, early-stage cancer detection above 95% in a blinded cohort, and a government-funded sepsis program in France, as highlighted by PRNewsWire.
VolitionRx also expands its Fujifilm agreement to include cats and reduces debt by more than $5 million, as highlighted by PRNewsWire. The company is discussing licenses with more than a dozen diagnostic and liquid biopsy companies worldwide.
VolitionRx says more than 70 patents protect its platform. It aims to co-develop and license the technology in exchange for upfront payments, milestone payments and royalties. The stock’s one-year range is $0.16 to $7.80, and its market capitalization is about $2.27 million.
Market news, earnings, and analyst coverage
Tony Dante writes market news and earnings coverage for the FMP blog, reporting on quarterly results, analyst rating changes, and company developments. His posts turn timely market events into concise, data-backed analysis for readers tracking individual names and sectors.
Financial data for every need
Real-time quotes and 30+ years of historical data, including prices, fundamentals, and insider transactions — all accessible via API.
Create Free Account